Cronos Group (CRON) Scheduled to Post Quarterly Earnings on Tuesday

Cronos Group (NASDAQ:CRON) is set to post its quarterly earnings results before the market opens on Tuesday, November 13th. Analysts expect Cronos Group to post earnings of $0.01 per share for the quarter.

Shares of CRON opened at $8.55 on Friday. The company has a current ratio of 52.98, a quick ratio of 44.71 and a debt-to-equity ratio of 0.02. The company has a market cap of $1.74 billion and a P/E ratio of 855.00. Cronos Group has a 1 year low of $2.52 and a 1 year high of $15.30.

Several equities analysts recently issued reports on the stock. Zacks Investment Research raised shares of Cronos Group from a “hold” rating to a “buy” rating and set a $9.25 price objective on the stock in a research note on Tuesday, November 6th. Canaccord Genuity raised shares of Cronos Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 15th. Finally, Cann assumed coverage on shares of Cronos Group in a research note on Friday, October 12th. They set a “sell” rating and a $4.50 price objective on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $6.88.

WARNING: “Cronos Group (CRON) Scheduled to Post Quarterly Earnings on Tuesday” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/11/11/cronos-group-cron-scheduled-to-post-quarterly-earnings-on-tuesday.html.

Cronos Group Company Profile

Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations “MMPR”. The firm typically invests in companies based in Canada.

Further Reading: Book Value Per Share in Stock Trading

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply